2nd Annual Midwest Melanoma Partnership Meeting

The Midwest Melanoma Partnership (MMP) is a multi-institutional group of physicians, scientists and patient advocates dedicated to the development of improved therapies for patients with malignant melanoma. The purpose of this activity is to promote collaborative clinical studies built upon the expertise of a multidisciplinary, multi-institutional team of scientists and physicians.

The morning meeting sessions (only open to partnership members), will be followed by an afternoon CME conference on brain metastases from melanoma. This event is open to anyone with an interest in melanoma prevention, treatment and research. This multidisciplinary conference will provide clinicians with information on state-of-the-art treatment and diagnostic modalities, therapeutic management and clinical support issues, that are relevant to a unique and challenging patient population.

EDUCATIONAL OBJECTIVES

Following this program, participants should be able to:

ªOutline advances in melanoma pathobiology, diagnosis, risk stratification, and biomarkers

ªIdentify advances in the understanding of genetic and molecular markers for treatment of metastatic melanoma

ªUnderstand changes in the signs and symptom in a patient to diagnose metastasis to the brain even while undergoing treatment for systemic disease

ªAssess the influence genetic and molecular markers on choosing and personalizing therapy in patients with metastatic melanoma

ªDescribe how to select therapy, manage side effects, and assess response in patients being treated for brain metastatic melanoma

ªEvaluate data from melanoma clinical trials and novel clinical trial designs to bridge the gap of unmet needs in the melanoma field

Abstract Submission

Abstracts submitted for review will only be accepted if they are in .doc, .docx or .txt format. The abstract can be up-loaded during the registration process. For details on the format requirements, go to the "Call for Abstracts" tab at the top of this page.

All abstracts must be submitted by March 29, 2013. You will be notified of the status of your submission by April 3, 2013.

When
Friday, April 12, 2013
9:00 AM - 5:00 PM